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A b s t r a c t 
 
Non-functionalized and amino-functionalized mesoporous silica nanoparticle were loaded 
with anti-inflammatory drug budesonide and additionally post-coated with bioadhesive 
polymer (carbopol). TEM images showed spherical shape of the nanoparticles and slightly 
higher polydispersity after coating with carbopol. Nitrogen physisorption and 
thermogravimetic analysis revealed that more efficient loading and incorporation into the 
pores of nanoparticles was achieved with the amino-functionalized silica carrier. Infrared 
spectra indicated that the post-coating of these nanoparticles with carbopol led to the 
formation of bond between amino groups of the functionalized carrier and carboxyl groups of 
carbopol. The combination of amino-functionalization of the carrier with the post-coating of 
the nanoparticles sustained budesonide release. Further, an in vitro model of inflammatory 
bowel disease showed that the cytoprotective effect of budesonide loaded in the post-coated 
silica nanoparticles on damaged HT-29 cells was more pronounced compared to the 
cytoprotection obtained with pure budesonide. 
 
 
1. Introduction 
 
Recently, research has been focused on the application of mesoporous silica based materials 
as a potential drug delivery system  [1–5]. Mesoporous silica nanoparticles have high surface 
area and large pore volume that enable drug loading  [6]. The mesoporous silica carriers could 
be functionalized with different organic groups (chloropropyl, phenyl, benzyl, 
mercaptopropyl, cyanopropyl, butyl groups) that additionally could improve their loading 
capacity  [7–9]. Sulfadiazine possessing amino functional groups has been loaded in a higher 
degree in carboxyl functiona-lized silica carrier than in non-functionalized due to electrostatic 
binding  [10]. Further, the formation of bonds could modify the release process, in particular 
could reduce the initial burst effect and could sustain the release rate of the incorporated drug  
[11–13]. For instance, erythromycin release from functionalized SBA-15 mesoporous silica 
was much slower compared to the release from unmodified material  [11]. The surface 
modification of mesoporous silica nanoparticles with polymers is another approach intended 
for reduction of the initial burst release  [14–17]. In addition, the surface modification could 
improve the interactions between nanoparticles and cells  [18–20]. The mod-ification of 
mesoporous silica nanoparticles is an intensively developing field associated with some 
difficulties. For instance, drug loading into modified carriers could be hindered due to the 
partial blocking of the pore entrance. To overcome this drawback, drug loading could be 
performed at specific conditions, e.g. loading of doxorubicin in mesoporous carriers modified 
with poly (acrylic acid) was carried out in a buffer with pH of 7.4 to enable electrostatic 
interaction between negatively charged carboxyl groups of polymer and positively charged 
doxorubicin  [21]. Another method for surface modification could be post-coating of 
mesoporous particles that are preliminary loaded with a drug. 
Budesonide is a nonhalogenated glucocorticosteroid possessing potent local anti-
inflammatory activity that is used for the treat-ment of asthma, non-infectious rhinitis and 
inflammatory bowel diseases. A tendency towards an increase in inflammatory bowel 
diseases, among which ulcerative colitis and Crohn's disease, has been noticed worldwide  
[22]. Ulcerative colitis affects mainly the colon mucosa, whereas Crohn’s disease affects the 
distal segments of the ileum. That is why the efforts in the recent years are pointed at 
preparation of appropriate budesonide delivery system with a local anti-inflammatory effect. 
However, the inflammation could affect gastrointestinal transit and drug absorption after oral 
administration. On the other hand, since budesonide has been identified as a P-glycoprotein 
substrate, its absorption could also be influenced by the P-glycoprotein efflux  [23]. Thus, the 
efficient oral therapy with budesonide will depend on the capacity of drug delivery system to 
release budesonide in the distal parts of GIT (e.g. ileum and colon), and the ability to prolong 
its residence time in these regions [24]. One of the approaches that could prolong 
gastrointestinal residence is the incorporation of the drug into nanoparticles. In addition, 
depending on the properties of the nanoparticle carrier the release rate of budesonide could be 
adjusted. 
In the present study, surface modification of the mesoporous nanoparticles was considered in 
order to provide low initial release and longer budesonide residence in gastrointestinal tract. 
The longer residence could be of a great importance taking into account that histological 
analyses showed high accumulation of silica nanoparticles in inflamed colon tissue  [25]. For 
this reason, carbopol was selected as modifying agent mainly because of its capacity for 
strong bioadhesive interactions that could prolong drug residence. Further, formation of 
polymer layer around nano-particles could reduce the rapid burst release providing that high 
concentration of budesonide would reach the distal segments of the tract. The modification 
was invented as post-coating of the budesonide loaded particles because preliminary 
modification of the carriers could hinder drug loading into pores. 
 
 
2. Materials and methods 
 
2.1. Materials 
 
Budesonide, 3-aminopropyltriethoxysilane (APTES), tetraethyl orthosilicate (TEOS) and N-
hexadecyltrimethylammoniumbromide (C16TMABr) were purchased from Aldrich. HEP G2 
and HT-29 cells were obtained from the German Collection of Microorganisms and Cell 
Cultures (DSMZ GmbH, Braunschweig, Germany). All other solvents and reagents were of 
analytical grade. 
 
 
2.2. Synthesis of MCM-41 mesoporous silica carrier 
 
MCM-41 was prepared according to the procedure of Huh et al.  [26]. This sol–gel procedure 
is carried out at 353 K without a co-solvent, only in water solution and with NaOH as a 
catalyst. The relative molar composition of the reaction mixture was 1 TEOS: 0.12 
C16TMABr:0.31 NaOH:1190 H2O. The formed gel was aged at 353 K for 2 h, then washed 
with distilled water until neutral pH, and dried at ambient. Template removal of MCM-41 
materials was carried out in air at 823 K with 1 K/min rate for 5 h. 
 
 
2.3. Modification of the carrier by APTES 
 
Modification of the spherical MCM-41 material with amino groups was accomplished by 
reacting with 3-aminopropyltriethoxysilane (APTES) (24 h, 333 K) in toluene. After the 
reaction, the materials were washed with several portions of toluene, methanol and finally 
water. 1 g of the silica was reacted with 20 ml APTES in 100 ml toluene. The modified 
samples by APTES were designated as MCM-41NH2. 
 
 
2.4. Budesonide loading and post-coating of the mesoporous nanoparticles 
 
Mesoporous carriers were incubated with budesonide in ethanol under continuous magnetic 
stirring for 24 h at 310 K. Briefly, 100 mg of budesonide was dissolved in 2.5 ml of ethanol 
and 100 mg of dried mesoporous silica was put into this solution. After 24 h, the mixture was 
centrifuged at 15,000 rpm, rinsed with purified water, separated by a second centrifugation, 
and finely dried at room temperature under vacuum. 
For the coating procedure, drug loaded particles were incubated in an aqueous phase 
containing carbopol (0.012 wt%) under gentle stirring (100 rpm) for 2 h. After incubation, the 
dispersions were centrifuged at 15,000 rpm for 15 min, rinsed with distilled water, separated 
by a second centrifugation, and finely dried at room temperature under vacuum. The amount 
of budesonide in the supernatants was measured by UV-spectrophotometry at a wavelength of 
250 nm (Hewllet Packard 8452 A). The concentration of budesonide was calculated according 
to the standard curve prepared in the concentration range of 7–28 μg/ml (r>0.994). The 
samples were abbreviated as MCM-41budC and MCM-41NH2budC. 
 
 
2.5. Characterization of the nanoparticles 
 
X-ray diffractograms were recorded by a Philips PW 1810/3710 diffractometer with Bregg–
Brentano parafocusing geometry apply-ing monochromatized CuKα (λ=0.15418 nm) radiation 
(40 kV, 35 mA) and proportional counter. 
Nitrogen physisorption measurements were carried out at 77 K using Quantachrome 
NOVA Automated Gas Sorption Instrument. The pore-size distributions were calculated from 
the desorption branch of the isotherms with the BJH method. Samples were pretreated at 353 
K for 5 h before measurements.  
TEM images were taken by using a MORGAGNI 268D TEM (100 kV; W filament; point-
resolution 0.5 nm). 
Attenuated total reflection infrared (ATR-FTIR) spectra were recorded by means of a Varian 
Scimitar 2000 FTIR spectrometer equipped with a MCT (mercury–cadmium–tellur) detector 
and a single reflection ATR unit (SPECAC “Golden Gate”) with a diamond ATR element. In 
general, 128 scans and 4 cm
_1
 resolution were applied. For all spectra ATR-correction was 
performed (Varian ResPro 4.0 software). 
Determinations of nanoparticle size, polydispersity index and zeta potential were performed 
using a Zetasizer (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, UK). The 
samples were dispersed in distilled water and measured at a scattering angle of 90° and 25°. 
The budesonide loading was determined by thermogravimetric measurements performed with 
a Setaram TG92 instrument with a heating rate of 5 K/min in nitrogen flow. 
 
 
 
2.6.  In vitro release studies 
 
For in vitro release studies, 10 mg of the drug loaded nanoparticles were incubated in 200 ml 
acid or phosphate buffer (pH=1.2 or 6.8) at 310 K under stirring (100 rpm). Samples were 
withdrawn (5 ml) at appropriate time intervals, centrifuged at 15,000 rpm for 15 min, and 
replaced by fresh buffer (pH=1.2 or 6.8). The concentration of the released budesonide in the 
samples was deter-mined by UV–vis spectrophotometry at a wavelength of 250 nm (Hewllet 
Packard 8452 A) as described above. 
 
 
2.7.  In vitro cytotoxicity 
 
The HEP G2 were placed into 75 cm
2
 tissue culture flasks and grown at 310 K under a 
humidified 5% CO2 atmosphere in 90% DMEM with 2 mM glutamine containing 1.5 g/l 
sodium bicarbonate and supplemented with 10% fetal bovine serum and 2% penicillin–
streptomycin (10,000 U/ml penicillin and 10 mg/ml streptomycin) (Gibco BRL). 
HEP G2 cells were placed in a 96-well plate at a density of 2 x 10
5
 cells/well and allowed to 
attach to the well surface for 24 h at 310 K, 5% CO2 and 95% air. Stock solutions of pure 
budesonide, empty and loaded carriers were freshly prepared in ethanol and thereafter diluted 
with growth medium to the desired concentrations (ethanol final concentration did not exceed 
0.2%). Different amounts (in the range of 0.1–1 mg ml-1) of budesonide loaded mesoporous 
silica particles were added to cells, and incubated for periods of 24 h and 48 h. Eight wells for 
each concentrations were used. To determine cell viability, lactate dehydrogenase leakage 
(LDH) from the cells was determined using a commercial LDH cytotoxicity detection kit 
according to the manufacturer’s protocols (Clontech, USA). Briefly, LDH activity is 
determined by colorimetric assay. In the first step, NAD+ is reduced to NADH/H+ by the 
LDH-catalyzed conversion of lactate to pyruvate. Then, a catalyst induced in the reaction 
mixture (diaforase) transfers H/H+ from NADH/H+ to the tetrazolium salt INT, which is 
reduced to a formazan dye. The amount of dye produced is proportional to the number of 
lysed (dead or plasma membrane damaged) cells. The formazan dye product shows an 
absorbance maximum at 490 nm. LDH activity was assessed in the conditioned media and the 
amounts detected were calculated as percentage of the solvent treated control (0.2% ethanol in 
DMEM growth medium) (GraphPadPrizm Software). 
 
 
2.8.  In vitro cytoprotective effect of budesonide loaded silica particles 
 
EOL-1 (ACC 386) cells originated from a patient with acute myeloid (eosinophilic) leukemia. 
HT-29 cells (human colon adenocarcinoma cell line) were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ GmbH, Braunschweig, Germany). 
For the study, EOL-1 and HT-29 cells were placed in the microplates at a density of 3 x 10
5
 
cells per ml and 1.5 x 10
5
 per ml, respectively. After a 24 h incubation period at 310 K, EOL-
1 cells were treated with 100 μg/ml phorbol 12-myristate 13-acetate (PMA) for 24 h and later 
were admixed to a HT-29 confluent monolayer. HT-29 cells were untreated (control) or 
pretreated with pure budesonide (5 or 10 μM) or budesonide loaded nano-particles. After 48 h 
incubation, the cells were rinsed with PBS and 3 ml of new medium (RPMI 1640) and 30 μl 
MTT solution were added to each well. The microplates were further incubated for 3 h at 310 
K and the MTT-formazan crystals formed were dissolved through the addition of 3 ml per 
well of 5% formic acid in 2-propanol. The MTT formazan absorption was determined using a 
microprocessor controlled microplate reader (Labexim LMR-1) at 550 nm. 
 
2.9. Statistical analysis 
 
The experiments were replicated three independent times and the data are presented as 
mean ±SEM. Statistical analysis was carried out using Student’s t test. Differences were 
considered statistically significant when P-value was less than 0.01. 
 
 
3. Results and discussion 
 
In this study amino-functionalization of mesoporous silica nanoparticles was performed in 
order to provide available functional groups for subsequent coating with carbopol. The 
coating was intended in order to reduce the burst release of budesonide as well as to achieve 
long residence of budesonide on intestinal mucosa due to bioadhesive properties of carbopol-
coated mesoporous nanoparticles. 
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Fig. 1. XRD patterns of initial (MCM-41) and amino-functionalized (MCM-41NH2) 
mesoporous particles 
 
3.1. Physicochemical characterization of the mesoporous nanoparticles 
 
XRD data of the initial (MCM-41) and the amino-functionalized (MCM-41NH2) samples 
with the intense (100) and higher Miller indices reflections in the low 2 theta region 
confirmed the formation of the hexagonal structure ( Fig. 1). Some intensity decrease and 
broadening of the 100 reflection are observed in the pattern of amino-functionalized MCM-41 
indicating partial structure deterioration. Broadening and shifting of the diffraction peaks 
were observed for the budesonide loaded samples, especially for the amino-functionalized 
one. This effect indicated more significant decrease in structural order in the case of 
functionalized drug loaded sample, which could be related to higher drug loading capacity. 
Also, the presence of crystalline budesonide phase was registered on the non-functionalized 
and the amino-functionalized samples. The latter evidenced that budesonide was not only 
contained in the mesopore channels, but could be found on the outer surface of the spherical 
particles or in the secondary mesopores, e.g. in the voids among the particles. 
Nitrogen adsorption and desorption isotherms of the samples are presented in Fig. 2 whereas 
the calculated textural parameters are presented in  Table 1. The isotherms of the initial and 
the amino-functionalized samples exhibited a sharp increase at a relative pressure of p/p0 = 
0.2–0.4, which was associated with capillary condensation in the channels and narrow pore 
size distribution ( Fig. 2). The isotherms of the MCM-41 samples were reversible and did not 
show any hysteresis loop. The textural parameters of budesonide loaded non-functionalized 
particles showed some decrease in the surface area, pore diameter and pore volume. The 
modification by APTES resulted in some decrease of the surface area, pore diameter and pore 
volume whereas the budesonide loading on functionalized MCM-41NH2 carrier led to a total 
pore filling. The prepared silica MCM-41 support is made up of 100 nm sized spherical 
particles, which can agglomerate and among them secondary mesopores are formed. These 
mesopores are much bigger than the channel system of the particles but also suitable to store 
the drug. The hysteresis loop of capillary condensation of nitrogen into these secondary 
mesopores at relative pressures near p/p0 =1 is observed for all samples ( Fig. 2). 
All mesoporous samples were characterized by FT-IR, verifying the presence of amino 
groups after functionalization and drug adsorption. The asymmetric stretching vibrations (Si–
O–Si) appeared at about 1090 cm-1 ( Fig. 3). The modification of MCM-41 samples by 
APTES resulted in the appearance of the bands at 2929 cm
-1
 and at 1540 cm
-1
, which was 
attributed to C–H and N–H stretching vibrations of aminopropyl anchored on the surface of 
the mesoporous carrier [17]. According to the literature, primary aliphatic amines absorb in 
the region 3450–3160 cm-1, resulting in a broad band of medium intensity [27]. In solid state, 
amine hydrohalides containing –NH3
+
 have an absorption of medium intensity at 3350–3100 
cm
-1
. Primary amines have a medium-to-strong absorption band in the 1650–1580 cm-1 
region. For –CH2NH3
+
 functional group, the asymmetric NH3
+
 deformation appears at 1615–
1560 cm
-1
 as a medium-to-strong band, while the symmetric NH3
+
 deformation appears 
around 1520–1480 cm-1 as a weak intensity band [27]. 
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Fig. 2. Nitrogen adsorption/desorption isotherms of initial (MCM-41) and amino-
functionalized (MCM-41NH2) mesoporous particles. 
 
 
Table 1 
Physico-chemical properties of the initial and amino-functionalized particles. 
Samples ao 
a
 BET PD 
b
 Pore Zeta 
 (nm) (m
2
/g) (nm) volume (cm
3
/g) potential (mV) 
MCM-41 4.43 1175 2.7 0.99 -12.17±1 
MCM-4141NH2 4.42 570 2.2 0.47 +34.17±2 
MCM-41Bud 4.42 473 2.4 0.40 -14.67±1 
MCM-41NH2Bud 4.45 62 n.d. 0.16 +35.37±3 
a Cell parameter (ao =2d100(3)
-1/2
). 
 
b Pore diameter and pore volume calculated by BJH method.  
 
 
The FT-IR spectrа of budesonide loaded particles showed the bands at 2962 and 1463 cm-1 
characteristic for C–H and phenyl bands, respectively. The presence of the band at 1555 cm-1 
in the spectra of the carbopol-coated amino-functionalized silicas was indicative for the 
formation of a COO
_–NH3
+
 bond between the polymer and amino groups on the outer surface 
of the carrier. In the case of carbopol-coated non-functionalized particles interaction between 
carboxyl groups of carbopol and silanol groups of the carrier was not observed. 
The zeta potential of the non-functionalized MCM-41 particles was negative whereas the 
positive value was measured for particles prepared with amino-functionalized carrier (MCM-
41NH2). These observations proved the successful functionalization and the presence of 
amino groups on the surface ( Table 1). The drug loading did not influence the surface charge 
of the amino-functionalized particles, which was an indication for the availability of the 
amino groups on the mesoporous surface for further interaction with the coating polymer.  
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Fig. 3. ATR-FTIR spectra of initial (MCM-41) and amino-functionalized (MCM-41NH2) 
mesoporous particles. 
 
 
A  
B  
Fig. 4 TEM images and particle size distribution of carbopol-coated mesoporos particles: 
MCM-41budC (A) and MCM-41NH2budC (B). 
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Fig. 5. Thermogravimetric profiles of initial and amino-functionalized budesonide loaded 
nanoparticles (MCM-41bud and MCM-41NH2bud) (A) and comparison of budesonide 
loading into the different nanoparticles (B). 
 
Determination of the size of budesonide loaded carbopol-coated particles showed that a 
fraction with a size 100 nm was about 70%, which was in a good accordance with TEM 
images ( Fig. 4). 
The budesonide loaded in the mesopores of the nanoparticles and pure budesonide were 
quantified using thermogravimetry (TG). The calculated amount of amino groups in the 
amino-functionalized MCM-41NH2 is around 2.5 wt%. The actual amount of the drug loading 
was determined after correcting the curves by water and aminopropyl content. The non-
functionalized MCM-41 showed lower adsorption capacity (40 wt%) for budesonide in 
comparison to its amino-functionalized analog (49 wt%) ( Fig. 5). Thermogravimetric profile 
of non-functionalized particles showed that about 71% of budesonide was decomposed in the 
interval 573–623 K, indicating that a significant part of budesonide was physically adsorbed 
outside the channels of non-functionalized carrier, probably in the secondary mesopores ( Fig. 
5A). The decomposition of non-loaded budesonide ( Fig. 5A) started at higher temperature 
than the loaded one. This observation is typical when the drug is finely dispersed on the 
support. The amount of budesonide loaded in the channels (decomposing above 500 K) was 
relatively lower (29%), whereas the whole amount of budesonide loaded on amino-
functionalized MCM-41NH2 was decomposed above 480 K. These results suggested that 
more efficient loading into the pores was achieved with the amino-functionalized carrier 
which is in a good accordance with the registered broadening and shifting of the diffraction 
peaks in their XRD patterns. This fact was explained with probable formation of hydrogen 
bonds between hydroxyl groups of budesonide and amino groups of the functionalized carrier. 
The coating of the drug loaded particles was not expected to influence the drug loading 
degree. Indeed, thermogravimetric measurements revealed similar loading for coated 
mesoporous nanoparticles with those for their non-coated analogs ( Fig. 5B). This observation 
was proved by the fact that during the coating procedure budesonide did not diffuse out from 
the particles probably due to the high viscosity of the coating solution. 
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Fig. 6. In vitro budesonide release from carbopol-coated MCM-41budC (empty columns) and 
carbopol-coated amino-functionalized MCM-41NH2budC (full columns) at pH=1.2 and 
pH=6.8. 
 
 
3.2. Drug delivery 
 
Release studies were performed in buffers with pH values 1.2 and 6.8 that are typically 
applied in order to mimic the in vivo conditions in gastrointestinal tract. The studies showed 
different profiles for coated and non-coated nanoparticles. Total budesonide release from non-
coated nanoparticles was registered in 1 h at both pH values (not shown). Thus, independent 
on the fact that almost the whole amount of budesonide was located into the pores of the 
amino-functionalized carrier the release was as fast as from non-functionalized carrier where 
a significant part of budesonide was adsorbed outside the pores. Further, the coating of 
particles prepared with non-functionalized carrier resulted in negligible prolongation ( Fig. 6). 
However, the combination of amino-functionalization of the carrier with the post-coating of 
the particles really sustained the release. As shown, 100% drug was released in 3 h from 
coated non-functionalized nanoparticles, whereas from the coated functionalized 
nanoparticles the drug was released in 24 h. The faster release from the coated non-
functionalized particles was explained with the lower stability of the coating layer. Since the 
FTIR spectra did not reveal formation of bonds between silanol groups and carboxyl groups 
of the carrier, the surface layer was most probably formed by simple physical adsorption. 
More stable coating layer was formed with amino-functionalized carrier because of the COO
-
–NH3
+
 bond between carboxyl groups of carbopol and the amino groups of the carrier as 
FTIR spectra showed. 
Drug loading degree could also influence the release process. However, the particles with 
similar loading released budesonide in different rates. In particular, non-coated and carbopol-
coated amino-functionalized particles had similar load of approximately 49% but different 
release rates. Consequently, drug release was influenced mainly by the coating rather than 
different drug loadings. 
The sustained release of budesonide was more pronounced at pH=6.8. The carbopol shell 
around amino-functionalized particles at acidic conditions will be protonated that facilitates 
the drug release whereas at high pH value an extended shell around the particles will be 
formed. This extended shell could hinder the budesonide release from the silica core at 
pH=6.8 ( Fig. 6). Song et al. [28] prepared pH responsive membranes by grafting poly 
(acrylic acid) onto the silica–aluminum. The authors found high water permeation at low pH, 
which is in good agreement with our observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. LDH release from HEP G2 cells treated with the budesonide loaded mesoporous silica 
nanoparticles: 24 h and 48 h exposure (A and B, respectively). Mean ± SD (n=3). 
 
 
3.3. In vitro cytotoxicity 
 
HEP G2 cells were selected for the study since they resemble functionally and 
morphologically normal hepatocytes. The in vitro cytotoxicity of the mesoporous 
nanoparticles was measured in HEP G2 cells using lactate dehydrogenase (LDH) assay to 
evaluate the integrity of cell membrane. First, the ability of the carriers and free budesonide to 
interfere with the cell membrane integrity was studied. Both the carriers and budesonide were 
practically devoid of cytotoxic effect by means of their LDH leakage (data not shown). 
Further, budesonide loaded non-coated particles (MCM-41Bud and MCM-41NH2Bud) were 
incubated on HEP G2 cells and LDH leakage was determined in 24 h and 48 h. After 24 h 
incubation time, both types of the particles showed an increase in LDH leakage suggesting 
changes in cell integrity. The increase was more prominent with the higher dose tested (1 
mg/ml) (by 50% and by 30% vs control, p<0.01, respectively) ( Fig. 7A). After 48 h exposure  
 
 
Fig. 8. Cytoprotective effect of free budesonide and budesonide loaded mesoporous silica 
nanoparticles (MCM-41NH2budC) on HT-29 cells damaged with phorbol-12-myristate-13-
acetate. Mean ± SD (n =3). 
 
at varying doses, HEP G2 cells viability resulted in adose-dependent decrease as detected by 
LDH leakage ( Fig. 7B). However, the viability of the cells incubated with the coated meso-
porous particles was different. Both types of carbopol-coated particles (MCM-41BudC and 
MCM-41NH2BudC) did not show statistically significant increase in LDH release (by 18% 
and by 2% vs. control, respectively). They were practically non-cytotoxic in the model of 
cellular population used in the study. Therefore, the coating of mesoporous silica with 
carbopol decreased the toxicity of the mesoporous drug delivery system. 
 
3.4. Cytoprotective effect 
 
In order to create an in vitro model of inflammatory bowel disease human mixed mononuclear 
cells (MMCs) were cocultured with HT-29 cells [29]. HT-29 cells (human colon 
adenocarcinoma cell line) can be used as in vitro model of intestinal mucosa because they 
have the characteristics of normal intestinal epithelium such as epithelial polarity, presence of 
the actin-binding protein villin, and the occurrence of an enterocytic differentiation  [30]. 
EOL-1 cells are known to respond to phorbol myristate acetate ester (PMA) treatment and 
they provide a useful experimental model for the study of differentiation and regulation of 
human eosinophils. Moreover, EOL-1 cells are suitable as an in vitro eosinophilic model for 
studying eosinophilic functions  [31,32]. 
Taking into account these considerations, PMA differentiated human EOL-1 cells were 
applied in a co-cultural model with HT-29 cells untreated or pretreated with pure budesonide 
or budesonide loaded nanoparticles. The addition of PMA treated EOL-1 cells caused about 
20% decrease of the cell viability of monolayer growing colon HT-29 cells. Pretreatment of 
HT-29 cells with 5 μM free budesonide did not protect cells from cytotoxic damage ( Fig. 8). 
The higher applied concentration of budesonide (10 μM) provided cytoprotective effect. More 
interestingly, the pretreatment with budesonide loaded silica nanoparticles (MCM-
41NH2budC) caused significant protection against the damage produced by PMA 
differentiated eosinophilic EOL-1 cells ( Fig. 8). Even the lower concentration of nanoparticle 
formulation (corresponding to 5 mM budesonide) resulted in statistically significant 
cytoprotective effect. Thus, the important finding was that the cytoprotection could be 
achieved at lower concentration of budesonide when loaded in mesoporous silica 
nanoparticles. Similarly, PEG-modified mesoporous silica nanoparticles loaded with 
hydralazine showed higher neuroprotective effect to PC12 neuronal cells damaged by 
exposure to acrolein than free hydralazine [33]. Controlled release of hydralazine and 
enhanced intracellular internalization were considered among the reasons for the significantly 
higher neuro-protective effect achieved with the mesoporous nanoparticles. In our study, the 
fact that the cytoprotection could be achieved at lower concentration by applying 
encapsulated budesonide could be explained with facilitated interaction of mesoporous 
nanoparticles with the cells. 
 
4. Conclusion 
 
Amino-functionalization of mesoporous silica particles resulted in higher loading degree 
compared to non-functionalized samples. On the other hand, the functionalization enabled the 
achievement of surface coating based on the interaction between amino groups of the carrier 
and carboxyl groups of carbopol. Both, the amino-functionalization and the coating, provided 
sustained release of budesonide during 24 h without initial burst effect. These particles 
provided cytoprotective effect on damaged model of intestinal mucosa at lower concentration 
than respective concentration of free budesonide. Thus, the development of modified silica 
nanoparticles loaded with budesonide could be considered as an alternative approach in the 
treatment of intestinal bowel diseases. 
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